Table 3.
Estimated HR for independent factors associated with SPK transplant outcomes
| Covariate | Reference | Levels | Unadjusted HR (95% CI) | P | Adjusted HR (95% CI) | P |
|---|---|---|---|---|---|---|
| Patient death | ||||||
| diabetes | T1DM | T2DM | 1.25 (0.97 to 1.59) | 0.08 | 1.10 (0.85 to 1.42) | 0.44 |
| recipient age | ≤45 years | >45 years | 1.39 (1.19 to 1.62) | <0.001 | 1.29 (1.10 to 1.52) | 0.002 |
| pretransplant dialysis | Pre-emptive | >1 year | 1.56 (1.26 to 1.94) | <0.001 | 1.57 (1.26 to 1.94) | <0.001 |
| CAD | No | Yes | 1.51 (1.23 to 1.86) | <0.001 | 1.27 (1.02 to 1.57) | 0.03 |
| PVD | No | Yes | 1.51 (1.17 to 1.93) | 0.001 | 1.34 (1.03 to 1.73) | 0.03 |
| EPD | Enteric | Bladder | 1.37 (1.13 to 1.64) | 0.001 | 1.29 (1.02 to 1.57) | 0.01 |
| calcineurin inhibitors | No drug | Cyclosporine | 0.49 (0.32 to 0.58) | <0.001 | 0.46 (0.32 to 0.65) | <0.01 |
| Tacrolimus | 0.33 (0.27 to 0.42) | <0.001 | 0.40 (0.30 to 0.52) | <0.01 | ||
| AP drug | No drug | MMFa | 0.43 (0.34 to 0.54) | <0.001 | 0.69 (0.53 to 0.90) | 0.007 |
| donor COD | No CVD | CVD | 1.38 (1.16 to 1.63) | <0.001 | 1.18 (0.98 to 1.42) | 0.07 |
| donor age | ≤45 years | >45 years | 1.60 (1.27 to 2.02) | <0.001 | 1.29 (1.00 to 1.66) | 0.04 |
| Overall kidney graft loss | ||||||
| diabetes | T1DM | T2DM | 1.29 (1.07 to 1.55) | 0.007 | 1.16 (0.95 to 1.39) | 0.136 |
| ethnicity | Caucasian | AA | 1.55 (1.34 to 1.80) | <0.001 | 1.51 (1.29 to 1.76) | <0.001 |
| BMI | 18.5% to 25% | >30% | 1.29 (1.09 to 1.54) | 0.003 | 1.25 (1.05 to 1.49) | 0.01 |
| pretransplant dialysis time | Pre-emptive | >1 year | 1.29 (1.11 to 1.51) | 0.001 | 1.26 (1.07 to 1.47) | 0.004 |
| steroid | No drug | Yes | 0.51 (0.41 to 0.63) | <0.001 | 0.76 (0.60 to 0.97) | 0.03 |
| calcineurin inhibitors | No drug | Cyclosporine | 0.43 (0.34 to 0.56) | <0.001 | 0.53 (0.41 to 0.70) | <0.001 |
| Tacrolimus | 0.37 (0.31 to 0.44) | <0.001 | 0.46 (0.34 to 0.46) | <0.001 | ||
| AP drug | No drug | MMFa | 0.46 (0.39 to 0.55) | <0.001 | 0.72 (0.58 to 0.89) | 0.003 |
| HLA mismatch | 0 | 5 to 6 | 1.27 (0.87 to 1.86) | <0.001 | 1.44 (0.98 to 2.11) | 0.06 |
| CIT | <12 hours | >24 hours | 1.31 (1.13 to 1.52) | <0.001 | 1.26 (1.09 to 1.46) | 0.002 |
| donor COD | Others | CVD | 1.33 (1.16 to 1.52) | <0.001 | 1.19 (1.04 to 1.38) | 0.01 |
| donor age | ≤45 years | >45 years | 1.56 (1.30 to 1.87) | <0.001 | 1.38 (1.14 to 1.67) | 0.001 |
| Overall pancreas graft loss | ||||||
| diabetes | T1Dm | T2DM | 1.15 (0.96 to 1.35) | 0.109 | 1.08 (0.91 to 1.28) | 0.39 |
| ethnicity | Caucasian | AA | 1.28 (1.12 to 1.47) | <0.01 | 1.25 (1.08 to 1.43) | 0.002 |
| BMI | 18.5% to 25% | >30% | 1.34 (1.15 to 1.55) | <0.001 | 1.31 (1.13 to 1.53) | <0.001 |
| pretransplant dialysis time | Pre-emptive | >1 year | 1.20 (1.05 to 1.37) | 0.005 | 1.20 (1.05 to 1.38) | 0.006 |
| calcineurin inhibitors | No drug | Cyclosporine | 0.52 (0.42 to 0.65) | <0.001 | 0.62 (0.48 to 0.79) | <0.001 |
| Tacrolimus | 0.43 (0.37 to 0.49) | <0.001 | 0.51 (0.42 to 0.62) | <0.001 | ||
| AP drug | No drug | MMFa | 0.51 (0.43 to 0.59) | <0.001 | 0.69 (0.57 to 0.83) | <0.001 |
| SRL | 0.49 (0.40 to 0.61) | <0.001 | 0.66 (0.52 to 0.83) | <0.001 | ||
| donor COD | Others | CVD | 1.36 (1.21 to 1.53) | <0.001 | 1.22 (1.07 to 1.37) | 0.002 |
| donor age | ≤45 years | >45 years | 1.61 (1.37 to 1.88) | <0.001 | 1.40 (1.17 to 1.65) | <0.001 |
Results are presented as HR with 95% CI.
a
Includes nonenteric and enteric formulations.